NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, announced that a National Bureau of Economic Research (NBER) research project will use industry benchmark cost data from Medidata Grants Manager® and Medidata CRO Contractor® to investigate the major causes of increasing drug development costs. The study, led by NBER Research Associates Iain Cockburn, a professor of finance and economics at Boston University School of Management, and Ernst Berndt, a professor in applied economics at MIT Sloan School of Management, examines the feasibility of constructing price indexes for clinical trials.
